Conference Coverage
Conference Coverage
Transplant waiting-list registrations dropped after direct acting–antiviral approval
The number of new waiting-list registrations for liver transplantation among patients with hepatitis C virus declined significantly after the...
Conference Coverage
Interferon-free treatment combo looks promising for HCV GT2, GT3 infection
The investigational combination of ombitasvir, paritaprevir, and ritonavir when given with sofosbuvir (OBV/PTV/r + SOF) appears to be a highly...
Conference Coverage
VIDEO: 12-week HCV retreatment effective if short course fails
Patients who fail short-course treatment for hepatitis C and show high levels of resistance to an antiviral drug may still respond to standard 12-...
Conference Coverage
Sofosbuvir/R yields benefits in compassionate use HCV program
In real-world setting, sofosbuvir in combination with ribavirin (SOF/R) provided meaningful benefits for special populations with hepatitis C...
Conference Coverage
VIDEO: Longer HCV therapy worked even after short-term failures
Patients with HCV who fail short-course antiviral treatment may still be able to achieve a cure using longer-duration therapies plus ribavirin.
Conference Coverage
Multitargeted drug combination promising when new HCV antivirals fail
Key clinical point: A five-drug antiviral combination appears to be effective for retreatment of patients with hepatitis C virus infection who...
Conference Coverage
Regimen effective in genotype 3 HCV despite advanced cirrhosis
Sustained virologic response in patients with genotype 3 hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis was achieved in 88%...
Conference Coverage
VIDEO: Antigen test could simplify HCV screening
A new test focused on hepatitis C antigen detection might simplify the HCV screening process and reduce its costs.
Conference Coverage
VIDEO: Inappropriate hepatitis A, B tests may be widespread in hospitals
Hospital physicians may be ordering too many inappropriate lab tests in cases of suspected acute hepatitis A and hepatitis B.
Conference Coverage
ASTRAL-1: High SVR12 with sofosbuvir/velpatasvir combo for HCV
Once-daily treatment with fixed-dose combination sofosbuvir/velpatasvir for 12 weeks was well tolerated and resulted in high sustained virologic...
Conference Coverage
High SVR achieved in decompensated HCV patients with 12-week therapy
The findings are encouraging because current treatment options for patients with HCV who have decompensated liver disease are limited, Dr....